title: [Topical inhibition of angiogenesis at the cornea. Safety and efficacy].
abstract: BACKGROUND
  The efficacy and safety of novel topical inhibitors of corneal neovascularisation will be discussed.
  
  
  METHODS
  A literature review after a PUBMED search and own clinical and experimental results are presented.
  
  
  RESULTS
  The off-label use of Avastin eye drops and GS101 eye drops against insulin receptor substrate (IRS)-1, which have been tested in phase II trial, both seem to be relatively efficient and safe ways to inhibit progressive corneal neovascularisation. Other VEGF antagonists, such as ranibizumab and pegaptanib eye drops also inhibit corneal neovascularisation.
  
  
  CONCLUSIONS
  Avastin and GS101 eye drops are the first specific angiogenesis inhibitors for topical inhibition of corneal angiogenesis available for clinical use.
authors.affiliation: Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen
authors.forename: B
authors.initials: B
authors.lastname: Regenfuss
authors.forename: F
authors.initials: F
authors.lastname: Bock
authors.forename: B
authors.initials: B
authors.lastname: Bachmann
authors.forename: Y
authors.initials: Y
authors.lastname: König
authors.forename: D
authors.initials: D
authors.lastname: Hos
authors.forename: A
authors.initials: A
authors.lastname: Parthasarathy
authors.forename: C
authors.initials: C
authors.lastname: Cursiefen
mesh_terms: D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy*; D006801:Humans; D009883:Ophthalmic Solutions / Q000008:administration & dosage* / Q000009:adverse effects; D000069579:Ranibizumab; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D009883:Ophthalmic Solutions; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab